Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer.

Aggarwal A, Yuan Z, Barletta JA, Lorch JH, Nehs MA.

Surgery. 2019 Sep 11. pii: S0039-6060(19)30458-1. doi: 10.1016/j.surg.2019.06.042. [Epub ahead of print]

PMID:
31521320
2.

Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma.

Wong KS, Lorch JH, Alexander EK, Marqusee E, Cho NL, Nehs MA, Doherty GM, Barletta JA.

Thyroid. 2019 Sep;29(9):1255-1261. doi: 10.1089/thy.2019.0263.

PMID:
31397224
3.

The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer.

Silva de Morais N, Stuart J, Guan H, Wang Z, Cibas ES, Frates MC, Benson CB, Cho NL, Nehs MA, Alexander CA, Marqusee E, Kim MI, Lorch JH, Barletta JA, Angell TE, Alexander EK.

J Endocr Soc. 2019 Mar 5;3(4):791-800. doi: 10.1210/js.2018-00427. eCollection 2019 Apr 1.

4.

Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.

Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, LeBoeuf NR, Schmults CD, Thakuria M, MacConaill LE, Hanna GJ.

Eur J Cancer. 2019 May;113:1-9. doi: 10.1016/j.ejca.2019.03.004. Epub 2019 Apr 4.

PMID:
30954880
5.

Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas.

Wong KS, Lorch JH, Alexander EK, Nehs MA, Nowak JA, Hornick JL, Barletta JA.

Thyroid. 2019 May;29(5):666-673. doi: 10.1089/thy.2018.0716. Epub 2019 Apr 16.

PMID:
30869569
6.

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing.

LaVigne AW, Margalit DN, Rawal B, Puzanov M, Annino DJ, Goguen LA, Sher DJ, Schoenfeld JD, Chau NG, Lorch JH, Rabinowits G, Haddad RI, Tishler RB.

Head Neck. 2019 Apr;41(4):959-966. doi: 10.1002/hed.25531. Epub 2019 Jan 8.

PMID:
30620435
7.

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD.

Oral Oncol. 2018 Oct;85:29-34. doi: 10.1016/j.oraloncology.2018.08.005. Epub 2018 Aug 17.

PMID:
30220316
8.

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.

Hanna GJ, Kacew A, Chau NG, Shivdasani P, Lorch JH, Uppaluri R, Haddad RI, MacConaill LE.

JCI Insight. 2018 Sep 6;3(17). pii: 122799. doi: 10.1172/jci.insight.122799. eCollection 2018 Sep 6.

9.

Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI.

JCI Insight. 2018 Feb 22;3(4). pii: 98811. doi: 10.1172/jci.insight.98811. eCollection 2018 Feb 22.

10.

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P.

J Immunother Cancer. 2018 Jan 19;6(1):7. doi: 10.1186/s40425-017-0310-x.

11.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

12.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

13.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

14.

Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.

Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH.

Int J Oral Maxillofac Surg. 2018 May;47(5):568-577. doi: 10.1016/j.ijom.2017.09.006. Epub 2017 Sep 29.

PMID:
28969885
15.

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy.

Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB.

Oral Oncol. 2017 Oct;73:160-165. doi: 10.1016/j.oraloncology.2017.08.012. Epub 2017 Sep 8.

PMID:
28939070
16.

A case of primary secretory carcinoma of the thyroid with high-grade features.

Wu EY, Lebastchi J, Marqusee E, Lorch JH, Krane JF, Barletta JA.

Histopathology. 2017 Oct;71(4):665-669. doi: 10.1111/his.13268. Epub 2017 Jul 13. No abstract available.

17.

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.

Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD.

Cancer Biomark. 2017;19(2):129-136. doi: 10.3233/CBM-160071.

PMID:
28387659
18.

Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.

Zhang Y, Waterboer T, Haddad RI, Miles BA, Wentz A, Gross ND, Fakhry C, Quon H, Lorch JH, Gourin CG, Clayburgh D, Misiukiewicz KJ, Richmon JD, Andersen PE, Posner MR, D'Souza G.

Oral Oncol. 2017 Apr;67:77-82. doi: 10.1016/j.oraloncology.2017.02.004. Epub 2017 Feb 15.

19.

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.

Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, Ivanova EV, Bittinger MA, Cavanaugh ME, Rode AJ, Schoenfeld JD, Chau NG, Haddad RI, Lorch JH, Wong KK, Uppaluri R, Hammerman PS.

Oral Oncol. 2017 Apr;67:61-69. doi: 10.1016/j.oraloncology.2017.02.005. Epub 2017 Feb 14.

PMID:
28351582
20.

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH.

Cancer. 2017 Jul 15;123(14):2642-2650. doi: 10.1002/cncr.30541. Epub 2017 Feb 21.

21.

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD Jr, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, Thomas T, Janne PA, Garraway LA, Carter SL, Beroukhim R, Lorch JH, Van Allen EM.

Clin Cancer Res. 2017 May 1;23(9):2367-2373. doi: 10.1158/1078-0432.CCR-16-2154-T. Epub 2016 Oct 17.

22.

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences.

Margalit DN, Rawal B, Catalano PJ, Haddad RI, Goguen LA, Annino DJ, Limaye SA, Lorch JH, Lavigne AW, Schoenfeld JD, Sher DJ, Tishler RB.

Oral Oncol. 2016 Oct;61:19-26. doi: 10.1016/j.oraloncology.2016.07.012. Epub 2016 Aug 6.

PMID:
27688100
23.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.

Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.

24.

Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial.

Lu W, Wayne PM, Davis RB, Buring JE, Li H, Macklin EA, Lorch JH, Burke E, Haddad TC, Goguen LA, Rosenthal DS, Tishler RB, Posner MR, Haddad RI.

Oncologist. 2016 Dec;21(12):1522-1529. Epub 2016 Aug 10.

25.

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD.

Br J Cancer. 2016 Jul 12;115(2):252-60. doi: 10.1038/bjc.2016.166. Epub 2016 Jul 5.

26.

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.

Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.

27.

Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.

Lorch JH, Hanna GJ, Posner MR, O'Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI.

Head Neck. 2016 Apr;38 Suppl 1:E1618-24. doi: 10.1002/hed.24289. Epub 2015 Nov 28.

PMID:
26614576
28.

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.

Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison ML, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Guo Y, Xiao W, Miles BA, Richmon JD, Andersen PE, Misiukiewicz KJ, Chung CH, Gerber JE, Rajan SD, D'Souza G.

JAMA Oncol. 2015 Oct;1(7):907-15. doi: 10.1001/jamaoncol.2015.2524.

PMID:
26226294
29.

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.

Chau NG, Lorch JH.

Oncologist. 2015 Jul;20(7):699-701. doi: 10.1634/theoncologist.2014-0476. Epub 2015 Jun 3. No abstract available.

30.

Single-Session CT-Guided Percutaneous Microwave Ablation of Bilateral Adrenal Gland Hyperplasia Due to Ectopic ACTH Syndrome.

Sarma A, Shyn PB, Vivian MA, Ng JM, Tuncali K, Lorch JH, Zaheer SN, Gordon MS, Silverman SG.

Cardiovasc Intervent Radiol. 2015 Oct;38(5):1335-8. doi: 10.1007/s00270-015-1056-9. Epub 2015 Mar 12.

PMID:
25762486
31.

Genomic analysis of metastatic cutaneous squamous cell carcinoma.

Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS.

Clin Cancer Res. 2015 Mar 15;21(6):1447-56. doi: 10.1158/1078-0432.CCR-14-1773. Epub 2015 Jan 14.

32.

Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH.

N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.

33.

Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?

Hanna GJ, Haddad RI, Lorch JH.

Oncologist. 2013;18(3):288-93. doi: 10.1634/theoncologist.2012-0286. Epub 2013 Feb 26. Review.

34.

Trastuzumab for the treatment of salivary duct carcinoma.

Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI.

Oncologist. 2013;18(3):294-300. doi: 10.1634/theoncologist.2012-0369. Epub 2013 Feb 21.

35.

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.

Lin CI, Whang EE, Lorch JH, Ruan DT.

Surgery. 2012 Dec;152(6):1142-9. doi: 10.1016/j.surg.2012.08.016.

PMID:
23158184
36.

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, Haddad RI, Cullen KJ.

Ann Oncol. 2011 May;22(5):1071-7. doi: 10.1093/annonc/mdr006. Epub 2011 Feb 11.

37.

Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group.

Lancet Oncol. 2011 Feb;12(2):153-9. doi: 10.1016/S1470-2045(10)70279-5. Epub 2011 Jan 11.

39.

Seeking alternative biological therapies: the future of targeted molecular treatment.

Lorch JH, Posner MR, Wirth LJ, Haddad RI.

Oral Oncol. 2009 Apr-May;45(4-5):447-53. doi: 10.1016/j.oraloncology.2008.08.009. Epub 2008 Nov 21. Review.

PMID:
19027348
40.

Induction chemotherapy in locally advanced head and neck cancer: a new standard of care?

Lorch JH, Posner MR, Wirth LJ, Haddad RI.

Hematol Oncol Clin North Am. 2008 Dec;22(6):1155-63, viii. doi: 10.1016/j.hoc.2008.08.004. Review.

PMID:
19010265
42.

Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells.

Lorch JH, Klessner J, Park JK, Getsios S, Wu YL, Stack MS, Green KJ.

J Biol Chem. 2004 Aug 27;279(35):37191-200. Epub 2004 Jun 16.

Supplemental Content

Loading ...
Support Center